Post hoc analysis of QUEST (3110 patients with HFrEF, LVEF <=40%): qiliqiangxin's effect on cardiovascular death or first HF hospitalisation was consistent across baseline LVEF categories (HRs 0.65-0.94; P interaction=0.28); lower LVEF was linked to worse outcomes.
Secondary analysisn = 3,110
Shen et al. The efficacy and safety of qiliqiangxin according to baseline ejection fraction in patients with heart failure and reduced ejection fraction in QUEST